Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

Early-onset depression is a treatable condition, and treatment is urgent for several reasons. If ignored, the early-onset depression can recur through life, and it is associated with such later ...

providing critical insight into how the medication, often described as a wonder drug, alleviates symptoms of major depression in ... Multiple Sclerosis Drug May Help With Poor Working Memory Nov.

Using computational models, the researchers studied how the brain’s reward-learning system functions in those with depression ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

Next up, Tremfya made a triumphant return to the 2024 roundup after falling off the rankings in 2023. The med's return came ...

It is now approved for adults with treatment-resistant depression (TRD ... Reimagining What's Possibl At the Veeva Commercial Summit in Madrid at the end of 2024, pharmaphorum web editor Nicole ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...

A child facing verbally or physically abusive treatment at home or school who has no means of escaping continuing injury is at elevated risk for developing depression. Situations may not be ...

Red light therapy is increasingly viewed as a promising treatment for wrinkles, acne, psoriasis, scars and sun-damaged skin, ...

AbbVie has reported new phase 3 data for its schizophrenia and bipolar disorder therapy Vraylar in treatment-resistant depression ... At the Veeva Commercial Summit in Madrid at the end of ...

Thanks to America's fixation with eating more protein, the market for protein bars has expanded. Because of this, protein bar ...